New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
12:29 EDTARWR, RBCN, HSP, ISRG, MDR, MDCO, GMOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as the second quarter began with the S&P 500 index hitting a record high. The Nasdaq, however, was the early leader and remains the session's best performer with an advance of about 1%. Manufacturing data from around the globe pointed to expansion in the U.S. and Europe last month, though the picture in China was clouded by conflicting surveys. ECONOMIC EVENTS: In the U.S., Markit's final print for the March manufacturing PMI held steady at 55.5, which was down from February's 57.1 reading and below expectations for it to have been bumped up to 56.0. ISM's manufacturing PMI for March inched up to 53.7 from February's 53.2 reading, though that was a hair below the consensus 53.9 forecast. Construction spending rose 0.1% in February, as expected. In Asia, China's official manufacturing PMI climbed to 50.3 in March, beating expectations for a modest decline to 50.1. Markit and HSBC's PMI reading, however, fell to an eight-month low of 48.0. In Europe, the final euro zone manufacturing PMI for the month was unchanged from a flash estimate of 53.0, extending the recovery in the regionís manufacturing sector to a ninth straight month. COMPANY NEWS: General Motors (GM), which has been a constant source of headlines of late due to its ongoing recall problems, reported that its March U.S. sales report has been delayed due to a computer systems issue that impacted dealer reporting. The company, whose CEO Mary Barra is on Capitol Hill today to give testimony about the automaker's handling of ignition switch issues linked to 13 deaths, said it expects to report its sales this afternoon before the close of business... Shares of Intuitive Surgical (ISRG) advanced 9% near noon after the company announced the FDA cleared the U.S introduction of its new da Vinci Xi Surgical System. Analysts at JPMorgan responded to the news by raising Intuitive Surgical's price target to $500 from $475, saying the new system is a significant positive with the potential to both drive a replacement cycle and further increase penetration and utilization of the company's products within hospitals. Leerink also sees today's news as a positive, but said it is uncertain exactly how many incremental system sales the da Vinci XI Surgical system will fuel and whether the features of Intuitive's new robot will lead to increased utilization into new surgery areas. The firm kept its Market Perform rating on Intuitive. MAJOR MOVERS: Among the notable gainers was Rubicon (RBCN), which rose 13% after the stock was upgraded to Overweight at JPMorgan citing a pick-up in demand for LEDs and sapphire covers. Also higher was Arrowhead Research (ARWR), which rose 12% after the company announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. Among the noteworthy losers was The Medicines Co. (MDCO), which slid 15% after a court ruled that the company failed to prove that Hospira's (HSP) generic Angiomax product infringed its patents. Also lower was McDermott (MDR), which slid 7% after warning that its first quarter results may differ "substantially" from the company's current expectation and filing to sell 10M tangible equity units. INDEXES: Near midday, the Dow was up 60.69, or 0.37%, to 16,518.35, the Nasdaq was up 45.98, or 1.1%, to 4,244.98, and the S&P 500 was up 7.07, or 0.38%, to 1,879.41.
News For GM;ISRG;RBCN;MDCO;HSP;ARWR;MDR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 22, 2015
16:37 EDTMDCOThe Medicines Co. to hold a conference call
Subscribe for More Information
14:33 EDTMDCOThe Medicines Co. antiplatelet drug approved by FDA
Subscribe for More Information
12:41 EDTGMHyundai nearing sponsorship agreement with NFL, Bloomberg reports
Subscribe for More Information
11:15 EDTGMGM activists not interested in merger with Fiat Chrysler, Financial Times says
General Motors (GM) activist holders have said they will not push for a merger with Fiat Chrysler (FCAU), reports the Financial Times. According to four people familiar with the matter, the activist contingent, which controls about 1.5% of GM shares, is more interested in cutting costs than embarking on a complicated merger transaction. One person close to the hedge funds said the investors believe consolidation makes sense but are unsure "that this particular consolidation makes sense." Reference Link
11:02 EDTGMGeneral Motors to invest $245M at Orion Assembly plant
General Motors said it will invest $245M and add 300 new jobs at its Orion Assembly plant to support launching an all-new vehicle program. "Orion Assembly is a breeding ground for manufacturing innovation,Ē said Cathy Clegg, GM North America vice president of Manufacturing and Labor Relations. "It serves as a model for how to engage the entire workforce at all levels to achieve success. The plant is up to the challenge of building this brand-new product, something itís never seen before." Investment in Orion totals $962M since the UAW and GM worked together to reopen the previously idled plant in 2010, the automaker announced in a statement. Today's announcement is a part of the $5.4B GM has announced it will invest in U.S. manufacturing over the next three years. Approximately $3.1B of the $5.4B has been identified, leaving $2.3B to be announced by year end.
10:41 EDTISRGOptions with increasing implied volatility
Subscribe for More Information
06:57 EDTGMCNH Industrial upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded CNH Industrial (CNHI) to Neutral saying the stock could find support until the potential General Motors (GM) and Fiat-Chrysler (FCAU) merger is resolved. The firm raised its price target for shares to $8.50 from $7.50.
06:08 EDTGMGeneral Motors to add over 243,000 hatcbacks to air bag recall, AP reports
Subscribe for More Information
June 19, 2015
10:50 EDTGMEPA proposes new rules for medium- and heavy-duty truck emissions
Subscribe for More Information
June 18, 2015
16:24 EDTGMOn The Fly: Top stock stories for Thursday
Stocks began the session in positive territory, adding to the late day move yesterday that followed Fed comments about the central bank's plans to raise benchmark interest rates gradually. Today's rally was broad based, as all 10 S&P sectors were in positive ground and the Nasdaq closed at a new all-time high. There were the usual headlines concerning Greece, but for at least one day, the U.S. market was able to ignore the European noise. ECONOMIC EVENTS: In the U.S., the consumer prices index rose 0.4% in the month of May, versus expectations for a 0.5% increase. The core reading, which removes food and energy prices, rose 0.1%, versus the expected increase of 0.2%. Initial jobless claims dipped 12,000 to 267,000 in the week ended June 13, versus expectations for 277,000 first-time claims. The Philadelphia Fed manufacturing survey climbed 8.5 points to 15.2 in June, topping expectations for a reading of 8. The leading indicators rose 0.7% to 123.1 in May, topping expectations for a rise of 0.4%. In Europe, International Monetary Fund chief Christine Lagarde reportedly said Greece wonít be given a grace period if it fails to make its scheduled payment to the fund on June 30. Meanwhile, finance ministers of euro area member states met today, after which Agence France-Presse reported that the talks ended with no deal on Greece. Bloomberg subsequently said that euro leaders plan to hold a summit to discuss Greece this coming Monday. COMPANY NEWS: Shares of Oracle (ORCL) dropped $2.17, or 4.84%, to $42.74 after the enterprise software, hardware and IT services provider reported lower than expected fourth quarter earnings per share and gave a lower than expected forecast for profit in its new quarter... General Motors (GM) announced that Fitch has raised the credit ratings of both GM and GM Financial to investment grade, meaning the corporate credit ratings for GM are now investment grade with all major rating agencies. Meanwhile, Reuters reported, citing several sources familiar with the matter, that the automaker has hired Goldman Sachs (GS) and Morgan Stanley (MS) to advise it as Fiat Chrysler (FCAU) CEO Sergio Marchionne attempts to gain the support of GM investors with the goal of forcing merger discussions with GM's board... Fitness tracker maker Fitbit (FIT) surged 48.4% to close at $29.68 in its first day of public trading. The company priced its initial public offering at $20 per share, topping expectations, and its closing price gives it a market value near $6B. MAJOR MOVERS: Among the notable gainers was Martha Stewart Living Omnimedia (MSO), which rose $1.35, or 26.27%, to $6.44 after The Wall Street Journal reported the company was nearing a deal to be acquired by Sequential Brands (SQBG), though the Journal said it was unable to learn the terms of the potential deal being discussed. Sequential Brands (SQBG) shares added 12.4% to close at $16.04 following the report. Also higher was Radius Health (RDUS), which gained $7.81, or 15.1%, to $59.54 after the company announced results from the six-month extension study for abaloparatide, its experimental treatment for osteoporosis. Among the noteworthy losers was Bankrate (RATE), which fell $2.60, or 18.77%, to $11.25 and was downgraded to Neutral from Buy at SunTrust after the company's revenue outlook came in well below the consensus forecast. INDEXES: The Dow gained 180.10, or 1%, to 18,115.84, the Nasdaq rose 68.07, or 1.34%, to 5,132.95, and the S&P 500 added 20.80, or 0.99%, to 2,121.24.
13:28 EDTGMFitch upgrades General Motors, GM Financial to investment grade
Subscribe for More Information
June 17, 2015
17:37 EDTGMGM hires advisers as Fiat Chrysler tries to force merger talks, Reuters says
Subscribe for More Information
13:05 EDTGMJ.D. Power: Japanese auto brands struggle to keep up with pace of improvement
With a significant year-over-year improvement, Korean brands continue to widen the quality gap with other automakers, while Japanese makes collectively fall below industry average for the first time in 29 years, according to the J.D. Power 2015 U.S. Initial Quality StudySM released today. Korean brands lead the industry in initial quality by the widest margin ever, averaging 90 PP100, which is an 11 PP100 improvement from 2014. For the first time in the study, European brands surpass Japanese brands, while domestic makes equal the Japanese for only a second time. Porsche (POAHY) ranks highest in initial quality for a third consecutive year, posting a score of 80 PP100. With a 20 PP100 improvement from 2014, Kia follows Porsche in the rankings at 86 PP100. This marks the first time in the history of the study that Kia has led all non-premium makes in initial quality. Jaguar (TTM), Hyundai (HYMLF) and Infiniti (NSANY) round out the top five nameplates. Infiniti is one of the most improved brands in the study, lowering its problem score by 31 PP100 from 2014. Reference Link
10:00 EDTMDROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:17 EDTMDRMcDermott initiated with an Outperform at Cowen
Subscribe for More Information
07:36 EDTARWRArrowhead receives regulatory clearance for additional Phase 2b ARC-520 studies
Arrowhead Research announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection, has been approved by Germanyís Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are expected shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies. The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1. For each patient, the duration of the study is approximately 33 weeks, from screening to the Day 169 follow-up visit. For each study, a planning interim analysis will be performed when 54 patients have completed their Day 71 visit. This analysis will be used to plan future studies only and will not impact the enrollment or conduct of Heparc-2002 and -2003. Based on the interim results, the company will decide whether higher multiple-doses would be likely to lead to increased activity, in which case higher doses may be evaluated in one or more additional studies. The primary objective of the 2002 and 2003 studies is to evaluate the depth of hepatitis B surface antigen decline in response to multiple doses of ARC-520 compared to placebo as a measure of drug activity. Secondary objectives include the assessment of safety and tolerability and multi-dose pharmacokinetics of ARC-520 when co-administered with entecavir or tenofovir, in addition to other exploratory objectives.
06:57 EDTISRGIntuitive Surgical volatility at low end of historic range
Subscribe for More Information
06:09 EDTGMGeneral Motors uses old Chevrolet Volt batteries to power IT building
Subscribe for More Information
June 16, 2015
07:21 EDTGMDana Holding could win key GM deal, says RBC Capital
Subscribe for More Information
05:29 EDTGMAlly Financial upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Ally Financial (ALLY) to Buy saying the company's balance sheet restructuring is being undervalued at current share levels. Goldman believes the loss of the General Motors (GM) business is being overly discounted in the valuation and raised its price target for shares to $27 from $24.50. The firm calls Ally one of the most attractive value investments in financials.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use